Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 176

Results For "CE"

8529 News Found

SMS Lifesciences India posts Q1 FY24 consolidated loss at Rs. 1.79 Cr
News | August 10, 2023

SMS Lifesciences India posts Q1 FY24 consolidated loss at Rs. 1.79 Cr

The company has reported total income of Rs. 75.26 crores during the period ended June 30, 2023


Lonza launches nebula absorbance reader for streamlined Endotoxin and Pyrogen testing
Digitisation | August 09, 2023

Lonza launches nebula absorbance reader for streamlined Endotoxin and Pyrogen testing

The instrument is fully integrated with Lonza’s latest WinKQCLSoftware to enable data integrity compliance, streamline training, and reduce validation burden


Lupin receives USFDA approval for fluocinolone acetonide body oil
Drug Approval | August 09, 2023

Lupin receives USFDA approval for fluocinolone acetonide body oil

Fluocinolone Acetonide Oil (RLD Derma-Smoothe/FS®) had estimated annual sales of USD 10 million in the U.S. (IQVIA MAT June 2023)


Brenntag partners with Qualifyze to enhance pharma audit offering
News | August 09, 2023

Brenntag partners with Qualifyze to enhance pharma audit offering

Qualifyze specializes in Good Practice audits (GxP) audits and covers a wide range of areas, including excipients, starting materials, packaging, sustainability


Torrent Pharmaceuticals posts Q1 FY 24 consolidated PAT at Rs. 378 Cr
News | August 08, 2023

Torrent Pharmaceuticals posts Q1 FY 24 consolidated PAT at Rs. 378 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2625 crores during the period ended June 30, 2023


Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
Drug Approval | August 06, 2023

Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP

The product is being launched in August 2023


Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations
Drug Approval | August 05, 2023

Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations

The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023